Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
D1000 Varejo Farma ParticipacoesBSP:DMVF3 -2.19%79 3-Year EBITDA Growth Rate is 14.60% as of Jun. 2026, which is 30% below its 10-year median of 20.80. GuruFocus rates BSP:DMVF3 with a GF Score™ of 79/100 and a GF Value™ of R$7.74 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 524 Healthcare Providers & Services companies, D1000 Varejo Farma Participacoes ranks better than 57.82% on this metric.
During the past 12 months, D1000 Varejo Farma Participacoes's average EBITDA Per Share Growth Rate was 26.60% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 14.60% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 19.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 9 years, the highest 3-Year average EBITDA Per Share Growth Rate of D1000 Varejo Farma Participacoes was 43.70% per year. The lowest was 6.40% per year. And the median was 20.80% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
D1000 Varejo Farma Participacoes 3-Year EBITDA Growth Rate Related Terms
For the Pharmaceutical Retailers subindustry, D1000 Varejo Farma Participacoes's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
D1000 Varejo Farma Participacoes 3-Year EBITDA Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, D1000 Varejo Farma Participacoes's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where D1000 Varejo Farma Participacoes's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 14.60% mean?
D1000 Varejo Farma Participacoes (BSP:DMVF3) has a 3-Year EBITDA Growth Rate of 14.60% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for D1000 Varejo Farma Participacoes and its competitors. This is 30% below median its historical median of 20.80. Over the past decade, D1000 Varejo Farma Participacoes' 3-Year EBITDA Growth Rate has ranged from 6.40 to 43.70. According to the industry distribution chart, D1000 Varejo Farma Participacoes ranks #221 out of 524 companies in the Healthcare Providers & Services industry, placing it in the top 42.2%.
Is D1000 Varejo Farma Participacoes' 3-Year EBITDA Growth Rate too high?
D1000 Varejo Farma Participacoes' current 3-Year EBITDA Growth Rate of 14.60% is 30% below median its 10-year median of 20.80. Over the past 10 years, this metric has ranged from a low of 6.40 to a high of 43.70. The Healthcare Providers & Services industry median 3-Year EBITDA Growth Rate is 10.20. D1000 Varejo Farma Participacoes' value of 14.60% is 43.1% above this industry median. Based on the distribution chart, D1000 Varejo Farma Participacoes ranks #221 out of 524 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, D1000 Varejo Farma Participacoes has a GF Score™ of 79/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does D1000 Varejo Farma Participacoes' 3-Year EBITDA Growth Rate compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, D1000 Varejo Farma Participacoes ranks #221 out of 524 companies for 3-Year EBITDA Growth Rate. This puts D1000 Varejo Farma Participacoes in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 10.20. D1000 Varejo Farma Participacoes' value of 14.60% is 43.1% above this benchmark. Historically, D1000 Varejo Farma Participacoes' own 3-Year EBITDA Growth Rate has ranged from 6.40 to 43.70 over the past decade. While the company's 10-year median is 20.80 vs. the industry median of 10.20, D1000 Varejo Farma Participacoes has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Healthcare Providers & Services company?
The median 3-Year EBITDA Growth Rate among Healthcare Providers & Services companies is 10.20, based on 524 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. D1000 Varejo Farma Participacoes's current 3-Year EBITDA Growth Rate of 14.60% is 43.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for D1000 Varejo Farma Participacoes and its competitors. For the Healthcare Providers & Services industry, the median 3-Year EBITDA Growth Rate is 10.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. D1000 Varejo Farma Participacoes's current 3-Year EBITDA Growth Rate is 14.60%, which is 30% below median its own 10-year median of 20.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is D1000 Varejo Farma Participacoes stock overvalued right now?
Based on GuruFocus' analysis, D1000 Varejo Farma Participacoes (BSP:DMVF3) is currently considered Modestly Undervalued. The stock's GF Value™ is R$7.74, compared to a current price of R$6.70 — trading 13.4% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 14.60%, which is 30% below median its 10-year median of 20.80 and 43.1% above the Healthcare Providers & Services industry median of 10.20. D1000 Varejo Farma Participacoes' overall GF Score™ is 79/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For D1000 Varejo Farma Participacoes (BSP:DMVF3), the current 3-Year EBITDA Growth Rate is 14.60% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is D1000 Varejo Farma Participacoes (BSP:DMVF3) Overvalued in 2026?
Based on GuruFocus' analysis, D1000 Varejo Farma Participacoes stock appears to be undervalued.
The current stock price of R$6.70 is trading 13.4% below its estimated GF Value™ of R$7.74.
GuruFocus considers D1000 Varejo Farma Participacoes to be Modestly Undervalued.
Key valuation signals for BSP:DMVF3:
3-Year EBITDA Growth Rate: 14.60% (30% below median its 10-year median of 20.80)
GF Value™: R$7.74 vs. price of R$6.70 (13.4% below fair value)
Industry Position: 43.1% above the Healthcare Providers & Services median (#221 of 524)
No single metric tells the full story. See the BSP:DMVF3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:DMVF3 has been successfully added to your 
